The research progress of relationship between microRNA-200a and the proliferation, metastasis, and prognosis of hepatocellular carcinoma_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

TANG Jianwei , XU Mingqing ,  ZHANG Ming

Department of Liver Surgery, West China Hospital of Sichuan University, Chengdu 610041, P. R. China;

Corresponding?author：

ZHANG Ming, Email: 48284728@qq.com

Keywords：

microRNA-200a; hepatocellular carcinoma; proliferation; metastasis; tumor marker; prognosis; review

DOI：

10.7507/1007-9424.201802035

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective The aim of this study is to review the relationship between microRNA (miR)-200a and the proliferation, metastasis, and prognosis of hepatocellular carcinoma (HCC) based on the previous relevant studies. Methods A systematic literature search was performed to identify the related studies. We summarized the expression level of miR-200a in HCC, its roles and mechanisms in proliferation, metastasis, and prognosis of HCC. Results The expressions of miR-200a were down-regulated in HCC tissue, cell, and patients’ serum. The normal expression or the overexpression of miR-200a could significantly inhibite the proliferation, invision, and metastasis of HCC. Moreover, the differentially expressed miR-200a in the tumor tissue or the patient’ serum was potentially valuable for the early diagnosis and prognostic predicting of HCC. Although there had been many advances on miR-200a in HCC, only a few biological functions had been identified. The underlying regulating mechanisms and more targeted genes of miR-200a still needed to be further studied. Conclusion miR-200a not only has an inhibitory effect on the proliferation, invasion, and metastasis of HCC, but also has a certain clinical application value in the early diagnosis and prognosis of HCC.

Citation： TANG Jianwei, XU Mingqing, ZHANG Ming. The research progress of relationship between microRNA-200a and the proliferation, metastasis, and prognosis of hepatocellular carcinoma. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2018, 25(9): 1130-1134. doi: 10.7507/1007-9424.201802035 Copy

1.	Mazzanti R, Arena U, Tassi R. Hepatocellular carcinoma: where are we? World J Exp Med, 2016, 6(1): 21-36.
2.	Hu MD, Jia LH, Liu HB, et al. Sorafenib in combination with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis. Eur Rev Med Pharmacol Sci, 2016, 20(1): 64-74.
3.	Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov, 2010, 9(10): 775-789.
4.	Iorio MV, Croce CM. microRNA involvement in human cancer. Carcinogenesis, 2012, 33(6): 1126-1133.
5.	Fang Y, Xue JL, Shen Q, et al. MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma. Hepatology, 2012, 55(6): 1852-1862.
6.	Yang X, Zhang XF, Lu X, et al. MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway. Hepatology, 2014, 59(5): 1874-1885.
7.	Zhang Y, Takahashi S, Tasaka A, et al. Involvement of microRNA-224 in cell proliferation, migration, invasion, and anti-apoptosis in hepatocellular carcinoma. J Gastroenterol Hepatol, 2013, 28(3): 565-575.
8.	Cao Q, Lu K, Dai S, et al. Clinicopathological and prognostic implications of the miR-200 family in patients with epithelial ovarian cancer. Int J Clin Exp Pathol, 2014, 7(5): 2392-2401.
9.	Park SM, Gaur AB, Lengyel E, et al. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev, 2008, 22(7): 894-907.
10.	Senfter D, Madlener S, Krupitza G, et al. The microRNA-200 family: still much to discover. Biomol Concepts, 2016, 7(5-6): 311-319.
11.	Murakami Y, Yasuda T, Saigo K, et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene, 2006, 25(17): 2537-2545.
12.	Feng J, Wang J, Chen M, et al. miR-200a suppresses cell growth and migration by targeting MACC1 and predicts prognosis in hepatocellular carcinoma. Oncol Rep, 2015, 33(2): 713-720.
13.	Wang J, Yang X, Ruan B, et al. Overexpression of miR-200a suppresses epithelial-mesenchymal transition of liver cancer stem cells. Tumour Biol, 2015, 36(4): 2447-2456.
14.	Dhayat SA, Hüsing A, Senninger N, et al. Circulating microRNA-200 family as diagnostic marker in hepatocellular carcinoma. PLoS One, 2015, 10(10): e0140066.
15.	Gregory PA, Bracken CP, Bert AG, et al. MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle, 2008, 7(20): 3112-3118.
16.	Xiao F, Zhang W, Zhou L, et al. microRNA-200a is an independent prognostic factor of hepatocellular carcinoma and induces cell cycle arrest by targeting CDK6. Oncol Rep, 2013, 30(5): 2203-2210.
17.	Chen SY, Ma DN, Chen QD, et al. MicroRNA-200a inhibits cell growth and metastasis by targeting Foxa2 in hepatocellular carcinoma. J Cancer, 2017, 8(4): 617-625.
18.	Zhong C, Li MY, Chen ZY, et al. MicroRNA-200a inhibits epithelial-mesenchymal transition in human hepatocellular carcinoma cell line. Int J Clin Exp Pathol, 2015, 8(9): 9922-9931.
19.	Garg M. Epithelial, mesenchymal and hybrid epithelial/ mesenchymal phenotypes and their clinical relevance in cancer metastasis. Expert Rev Mol Med, 2017, 19: e3.
20.	Baum B, Georgiou M. Dynamics of adherens junctions in epithelial establishment, maintenance, and remodeling. J Cell Biol, 2011, 192(6): 907-917.
21.	van Zijl F, Zulehner G, Petz M, et al. Epithelial-mesenchymal transition in hepatocellular carcinoma. Future Oncol, 2009, 5(8): 1169-1179.
22.	Kolesnikoff N, Attema JL, Roslan S, et al. Specificity protein 1 (Sp1) maintains basal epithelial expression of the miR-200 family: implications for epithelial-mesenchymal transition. J Biol Chem, 2014, 289(16): 11194-11205.
23.	Humphries B, Yang C. The microRNA-200 family: small molecules with novel roles in cancer development, progression and therapy. Oncotarget, 2015, 6(9): 6472-6498.
24.	Hung CS, Liu HH, Liu JJ, et al. MicroRNA-200a and -200b mediated hepatocellular carcinoma cell migration through the epithelial to mesenchymal transition markers. Ann Surg Oncol, 2013, 20 Suppl 3: S360-S368.
25.	Dhayat SA, Mardin WA, K?hler G, et al. The microRNA-200 family-a potential diagnostic marker in hepatocellular carcinoma? J Surg Oncol, 2014, 110(4): 430-438.
26.	Li R, Qian N, Tao K, et al. MicroRNAs involved in neoplastic transformation of liver cancer stem cells. J Exp Clin Cancer Res, 2010, 29: 169.
27.	Tu MJ, Pan YZ, Qiu JX, et al. MicroRNA-1291 targets the FOXA2-AGR2 pathway to suppress pancreatic cancer cell proliferation and tumorigenesis. Oncotarget, 2016, 7(29): 45547-45561.
28.	Wang J, Song W, Shen W, et al. MicroRNA-200a suppresses cell invasion and migration by directly targeting GAB1 in hepatocellular carcinoma. Oncol Res, 2017, 25(1): 1-10.
29.	Liu M, Liu J, Wang L, et al. Association of serum microRNA expression in hepatocellular carcinomas treated with transarterial chemoembolization and patient survival. PLoS One, 2014, 9(10): e109347.
30.	龔哲, 尚闖, 單國用, 等. 微小 RNA-200a 在肝癌患者血清及癌組織中的表達及其與預后的關系. 中華實驗外科雜志, 2015, 32(3): 608-610.
31.	Abu El Makarem M. An overview of biomarkers for the diagnosis of hepatocellular carcinoma. Hepat Mon, 2012, 12(10 HCC): e6122.
32.	Reichl P, Mikulits W. Accuracy of novel diagnostic biomarkers for hepatocellular carcinoma: an update for clinicians (review). Oncol Rep, 2016, 36(2): 613-625.
33.	Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A, 2008, 105(30): 10513-10518.
34.	Huang Z, Huang D, Ni S, et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer, 2010, 127(1): 118-126.
35.	Li G, Shen Q, Li C, et al. Identification of circulating microRNAs as novel potential biomarkers for hepatocellular carcinoma detection: a systematic review and meta-analysis. Clin Transl Oncol, 2015, 17(9): 684-693.
36.	Wang Y, Gao Y, Shi W, et al. Profiles of differential expression of circulating microRNAs in hepatitis B virus-positive small hepatocellular carcinoma. Cancer Biomark, 2015, 15(2): 171-180.
37.	汪建林, 戴斌, 楊西勝, 等. 肝癌患者血清中 miR-200a 的表達及其臨床意義. 中華臨床醫師雜志: 電子版, 2013, 7(23): 10422-10425.
38.	Sun X, He Y, Ma TT, et al. Participation of miR-200a in TGF-β1-mediated hepatic stellate cell activation. Mol Cell Biochem, 2014, 388(1-2): 11-23.
39.	Murray DD, Suzuki K, Law M, et al. Circulating miR-122 and miR-200a as biomarkers for fatal liver disease in ART-treated, HIV-1-infected individuals. Sci Rep, 2017, 7(1): 10934.

1. Mazzanti R, Arena U, Tassi R. Hepatocellular carcinoma: where are we? World J Exp Med, 2016, 6(1): 21-36.
2. Hu MD, Jia LH, Liu HB, et al. Sorafenib in combination with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis. Eur Rev Med Pharmacol Sci, 2016, 20(1): 64-74.
3. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov, 2010, 9(10): 775-789.
4. Iorio MV, Croce CM. microRNA involvement in human cancer. Carcinogenesis, 2012, 33(6): 1126-1133.
5. Fang Y, Xue JL, Shen Q, et al. MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma. Hepatology, 2012, 55(6): 1852-1862.
6. Yang X, Zhang XF, Lu X, et al. MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway. Hepatology, 2014, 59(5): 1874-1885.
7. Zhang Y, Takahashi S, Tasaka A, et al. Involvement of microRNA-224 in cell proliferation, migration, invasion, and anti-apoptosis in hepatocellular carcinoma. J Gastroenterol Hepatol, 2013, 28(3): 565-575.
8. Cao Q, Lu K, Dai S, et al. Clinicopathological and prognostic implications of the miR-200 family in patients with epithelial ovarian cancer. Int J Clin Exp Pathol, 2014, 7(5): 2392-2401.
9. Park SM, Gaur AB, Lengyel E, et al. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev, 2008, 22(7): 894-907.
10. Senfter D, Madlener S, Krupitza G, et al. The microRNA-200 family: still much to discover. Biomol Concepts, 2016, 7(5-6): 311-319.
11. Murakami Y, Yasuda T, Saigo K, et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene, 2006, 25(17): 2537-2545.
12. Feng J, Wang J, Chen M, et al. miR-200a suppresses cell growth and migration by targeting MACC1 and predicts prognosis in hepatocellular carcinoma. Oncol Rep, 2015, 33(2): 713-720.
13. Wang J, Yang X, Ruan B, et al. Overexpression of miR-200a suppresses epithelial-mesenchymal transition of liver cancer stem cells. Tumour Biol, 2015, 36(4): 2447-2456.
14. Dhayat SA, Hüsing A, Senninger N, et al. Circulating microRNA-200 family as diagnostic marker in hepatocellular carcinoma. PLoS One, 2015, 10(10): e0140066.
15. Gregory PA, Bracken CP, Bert AG, et al. MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle, 2008, 7(20): 3112-3118.
16. Xiao F, Zhang W, Zhou L, et al. microRNA-200a is an independent prognostic factor of hepatocellular carcinoma and induces cell cycle arrest by targeting CDK6. Oncol Rep, 2013, 30(5): 2203-2210.
17. Chen SY, Ma DN, Chen QD, et al. MicroRNA-200a inhibits cell growth and metastasis by targeting Foxa2 in hepatocellular carcinoma. J Cancer, 2017, 8(4): 617-625.
18. Zhong C, Li MY, Chen ZY, et al. MicroRNA-200a inhibits epithelial-mesenchymal transition in human hepatocellular carcinoma cell line. Int J Clin Exp Pathol, 2015, 8(9): 9922-9931.
19. Garg M. Epithelial, mesenchymal and hybrid epithelial/ mesenchymal phenotypes and their clinical relevance in cancer metastasis. Expert Rev Mol Med, 2017, 19: e3.
20. Baum B, Georgiou M. Dynamics of adherens junctions in epithelial establishment, maintenance, and remodeling. J Cell Biol, 2011, 192(6): 907-917.
21. van Zijl F, Zulehner G, Petz M, et al. Epithelial-mesenchymal transition in hepatocellular carcinoma. Future Oncol, 2009, 5(8): 1169-1179.
22. Kolesnikoff N, Attema JL, Roslan S, et al. Specificity protein 1 (Sp1) maintains basal epithelial expression of the miR-200 family: implications for epithelial-mesenchymal transition. J Biol Chem, 2014, 289(16): 11194-11205.
23. Humphries B, Yang C. The microRNA-200 family: small molecules with novel roles in cancer development, progression and therapy. Oncotarget, 2015, 6(9): 6472-6498.
24. Hung CS, Liu HH, Liu JJ, et al. MicroRNA-200a and -200b mediated hepatocellular carcinoma cell migration through the epithelial to mesenchymal transition markers. Ann Surg Oncol, 2013, 20 Suppl 3: S360-S368.
25. Dhayat SA, Mardin WA, K?hler G, et al. The microRNA-200 family-a potential diagnostic marker in hepatocellular carcinoma? J Surg Oncol, 2014, 110(4): 430-438.
26. Li R, Qian N, Tao K, et al. MicroRNAs involved in neoplastic transformation of liver cancer stem cells. J Exp Clin Cancer Res, 2010, 29: 169.
27. Tu MJ, Pan YZ, Qiu JX, et al. MicroRNA-1291 targets the FOXA2-AGR2 pathway to suppress pancreatic cancer cell proliferation and tumorigenesis. Oncotarget, 2016, 7(29): 45547-45561.
28. Wang J, Song W, Shen W, et al. MicroRNA-200a suppresses cell invasion and migration by directly targeting GAB1 in hepatocellular carcinoma. Oncol Res, 2017, 25(1): 1-10.
29. Liu M, Liu J, Wang L, et al. Association of serum microRNA expression in hepatocellular carcinomas treated with transarterial chemoembolization and patient survival. PLoS One, 2014, 9(10): e109347.
30. 龔哲, 尚闖, 單國用, 等. 微小 RNA-200a 在肝癌患者血清及癌組織中的表達及其與預后的關系. 中華實驗外科雜志, 2015, 32(3): 608-610.
31. Abu El Makarem M. An overview of biomarkers for the diagnosis of hepatocellular carcinoma. Hepat Mon, 2012, 12(10 HCC): e6122.
32. Reichl P, Mikulits W. Accuracy of novel diagnostic biomarkers for hepatocellular carcinoma: an update for clinicians (review). Oncol Rep, 2016, 36(2): 613-625.
33. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A, 2008, 105(30): 10513-10518.
34. Huang Z, Huang D, Ni S, et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer, 2010, 127(1): 118-126.
35. Li G, Shen Q, Li C, et al. Identification of circulating microRNAs as novel potential biomarkers for hepatocellular carcinoma detection: a systematic review and meta-analysis. Clin Transl Oncol, 2015, 17(9): 684-693.
36. Wang Y, Gao Y, Shi W, et al. Profiles of differential expression of circulating microRNAs in hepatitis B virus-positive small hepatocellular carcinoma. Cancer Biomark, 2015, 15(2): 171-180.
37. 汪建林, 戴斌, 楊西勝, 等. 肝癌患者血清中 miR-200a 的表達及其臨床意義. 中華臨床醫師雜志: 電子版, 2013, 7(23): 10422-10425.
38. Sun X, He Y, Ma TT, et al. Participation of miR-200a in TGF-β1-mediated hepatic stellate cell activation. Mol Cell Biochem, 2014, 388(1-2): 11-23.
39. Murray DD, Suzuki K, Law M, et al. Circulating miR-122 and miR-200a as biomarkers for fatal liver disease in ART-treated, HIV-1-infected individuals. Sci Rep, 2017, 7(1): 10934.

Previous Article
Advances of gastric cancer in imaging study
Next Article
Research progress of Warburg effect in colorectal cancer

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

The research progress of relationship between microRNA-200a and the proliferation, metastasis, and prognosis of hepatocellular carcinoma

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content